Relation between fatigue and ACR response in patients with psoriatic arthritis treated with TNFi therapy: a population-based cohort study.

Document Type

Article

Publication Date

11-15-2020

Publication Title

The Journal of rheumatology

Abstract

OBJECTIVE: The objective of this population-based cohort study was to investigate the association of fatigue with disease activity and drug survival in PsA patients receiving their first tumor necrosis factor inhibitor (TNFi).

METHODS: Data on patient characteristics, disease activity and drug survival were obtained from the DANBIO database on all PsA patients in the period 2006 through 2015. Information on comorbidities was obtained through linkage with the Danish National Patient Registry.

RESULTS: A total of 880 patients were eligible for analyses. Patients with upper median fatigue scores had statistically significant higher disease activity measure (DAS28CRP), pain and health assessment questionnaire (HAQ) scores, tender joint count, comorbidities (Charlson Comorbidity Index ≥2) and current smoking status at baseline compared to patients with lower median fatigue scores (p

CONCLUSION: Fatigue remains a dominating symptom after TNFi treatment, and is associated with higher baseline disease activity, pain and HAQ scores, more comorbidities, and increased risk of TNFi treatment discontinuation in a cohort of Danish patients with PsA. The agreement between ACR and VAS fatigue responses is weak to moderate suggesting heterogeneity between experienced fatigue and joint inflammation.

Clinical Institute

Orthopedics & Sports Medicine

Department

Orthopedics

Department

Rheumatology

Link to Full Text

PSJH Full Text

Share

COinS